EQS-Adhoc: Helen Giza is the new CEO of Fresenius Medical Care; Dr. Carla Kriwet leaves the company
| EQS-Ad-hoc: Fresenius SE & Co. KGaA / Key word(s): Personnel
Helen Giza is the new CEO of Fresenius Medical Care; Dr. Carla Kriwet leaves the company
05-Dec-2022 / 23:40 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Helen Giza is the new CEO of Fresenius Medical Care; Dr. Carla Kriwet leaves the company Today, the Supervisory Board of Fresenius Medical Care Management AG, the General Partner of Fresenius Medical Care AG & Co. KGaA, has unanimously appointed Helen Giza as CEO of the Management Board with effect as of 6 December 2022. Helen Giza continues to serve as Chief Financial Officer of Fresenius Medical Care until further notice. Her predecessor, Dr. Carla Kriwet is leaving the company at her own request and by mutual agreement due to strategic differences. As CEO of Fresenius Medical Care, Helen Giza will also join the Management Board of Fresenius Management SE. Dr. Carla Kriwet will leave the Management Board of Fresenius Management SE. Fresenius SE & Co. KGaA, represented by Fresenius Management SE, The Management Board Bad Homburg v.d.H., December 5, 2022 ---------------------------------------- Contact: Markus Georgi Senior Vice President Investor Relations & Sustainability T: +49 (0) 6172 608-2485 [email protected] ---------------------------------------- End of Note
05-Dec-2022 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
|
| Language: | English | | Company: | Fresenius SE & Co. KGaA | | Else-Kröner-Straße 1 | | 61352 Bad Homburg v.d.H. | | Germany | | Phone: | +49 (0)6172 608-2485 | | Fax: | +49 (0)6172 608-2488 | | E-mail: | [email protected] | | Internet: | www.fresenius.com | | ISIN: | DE0005785604 | | WKN: | 578560 | | Indices: | DAX | | Listed: | Regulated Market in Dusseldorf, Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Hamburg, Hanover, Stuttgart, Tradegate Exchange; Luxembourg Stock Exchange | | EQS News ID: | 1505587 |
| | | End of Announcement | EQS News Service |
1505587 05-Dec-2022 CET/CEST 
|
Die wichtigsten Finanzdaten auf einen Blick
|
| |
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023e |
| Umsatzerlöse1 |
33.530,00 |
35.409,00 |
37.250,00 |
36.277,00 |
37.520,00 |
40.840,00 |
22.299,00 |
| EBITDA1,2 |
6.267,00 |
6.032,00 |
7.083,00 |
7.132,00 |
6.854,00 |
6.808,00 |
3.422,00 |
| EBITDA-Marge3 |
18,69 |
17,04 |
19,01 |
19,66 |
18,27 |
16,67 |
|
| EBIT1,4 |
4.589,00 |
5.251,00 |
4.631,00 |
4.385,00 |
4.158,00 |
3.321,00 |
1.143,00 |
| EBIT-Marge5 |
13,69 |
14,83 |
12,43 |
12,09 |
11,08 |
8,13 |
5,13 |
| Jahresüberschuss1 |
1.816,00 |
1.871,00 |
1.915,00 |
2.823,00 |
2.819,00 |
2.117,00 |
-594,00 |
| Netto-Marge6 |
5,42 |
5,28 |
5,14 |
7,78 |
7,51 |
5,18 |
-2,66 |
| Cashflow1,7 |
3.937,00 |
3.742,00 |
4.263,00 |
6.549,00 |
5.078,00 |
4.198,00 |
4.456,00 |
| Ergebnis je Aktie8 |
3,25 |
3,37 |
3,44 |
3,06 |
3,26 |
2,44 |
-1,05 |
| Dividende8 |
0,75 |
0,80 |
0,84 |
0,88 |
0,92 |
0,92 |
0,62 |
Quelle: boersengefluester.de und Firmenangaben
Geschäftsbericht 2023 - Kostenfrei herunterladen. 
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: PricewaterhouseCoopers
|
| INVESTOR-INFORMATIONEN |
| ©boersengefluester.de |
| Fresenius |
| WKN |
Kurs in € |
Einschätzung |
Börsenwert in Mio. € |
| 578560 |
27,180 |
Halten |
15.308,79 |
| KGV 2025e |
KGV 10Y-Ø |
BGFL-Ratio |
Shiller-KGV |
| 13,07 |
16,61 |
0,79 |
10,94 |
| KBV |
KCV |
KUV |
EV/EBITDA |
| 0,81 |
3,44 |
0,69 |
8,35 |
| Dividende '22 in € |
Dividende '23e in € |
Div.-Rendite '23e
in % |
Hauptversammlung |
| 0,92 |
0,00 |
0,00 |
17.05.2024 |
| Q1-Zahlen |
Q2-Zahlen |
Q3-Zahlen |
Bilanz-PK |
| 08.05.2024 |
31.07.2024 |
06.11.2024 |
20.03.2024 |
| Abstand 60Tage-Linie |
Abstand 200Tage-Linie |
Performance YtD |
Performance 52 Wochen |
| 5,86% |
-0,06% |
-3,17% |
5,76% |
|
|
Fresenius SE & Co. KGaA DE0005785604